[{"from": "human", "value": "What can you tell me about this molecule? [C][O][C][=C][C][=Branch2][Ring2][O][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][#C][C][=N][N][Branch1][=C][C][=N][C][=N][C][=Branch1][=Branch1][=C][Ring1][=Branch2][Ring1][=Branch1][N][C@H1][C][C][N][Branch1][Ring2][C][Ring1][Branch1][C][=Branch1][C][=O][C][=C][O][C]"}, {"from": "gpt", "value": "The molecule is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and survival. FGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed in some cancers such as cholangiocarcinoma and urothelial malignancies.  As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma."}]